 When you started this three years ago, it was kind of a spur-of-the-moment thing. Would you talk about the initial idea, how it's progressed, and what it's become? Well, as you said, the idea was kind of spontaneous. We were excited to have a new program of biologics here at the Institute, and having Johnny here and Dr. Eward, we all know that he's a great scientist, but also he's very charismatic, and has a great relationship with different scientists across the country. So we just talked about it, and we said, well, let's invite our great minds and veil, great place to be, and let's have an exchange of ideas, because when you do bench research, multiple minds are certainly better than one, and we felt that having the catalyst of having Johnny being here, having the momentum was great to get it started. So we started small. Actually, it was not that small. We had only a couple of weeks to get ready, but it was a big success. I don't know how we pulled it off, but we did. And then it evolved. I'm amazed. I just got back from one of the sessions with Dr. Stoop, Dr. Murphy, and others, and I'm just amazed of the exchange of ideas that is upending right now. And it's a good camaraderie. It's a great camaraderie out there, and the topics are exciting, aging, stem cell, CRISPR technology, PRP. And I think for us as clinicians, having these great minds here in the veil for a few days is just an amazing resource, and it's very stimulating. And I think it's vice versa. These scientists are excited to come here to interact with us clinicians who treat the patient on a daily basis. So it's really evolving to a great conference, a work-class conference really here in our town. What did you get out of it this year? What are you more knowledgeable about or more inspired about from the last three days? Well, I should say, what did I get out of it? Because I got so much out of this. I just came back at lunchtime. I had a great exchange with scientists from Wisconsin, from Mayo, from Northwestern. And, you know, now I'm very optimistic about new avenues to treat my patient that are validated at the bench level and proven in the small animal model, large animal model. And now I'm very excited because pretty soon I'll have these applications available to me to treat my patient for courage defect, muscle injury, and have better outcome for our patients. So just over the past three years, I've seen the evolution. I was talking earlier about lasartan, which is a cardiac med. Now we, since the first conference, we've had immense progress. And I'm excited. I just got some data about a study we just completed with Dr. Eward. And now I have Sam Stude at Northwestern who's interested. And I have Dr. Murphy, Dr. Markell. I mean, it's amazing. I mean, to me, as a clinician, it's kind of a dream. I'm pinching myself. I think the future is bright. And most importantly, I think this collaboration and, again, the centerpiece is the patients, you guys. That's the centerpiece of all this because we want to treat better our patients. Not only the elite athletes, but the 80-year-old person who wants to keep snowshoeing up the mountain. And what's exciting is we have concrete research that I can see in our lifetime. Your lifetime, my lifetime will have better solution to common problems. And it's going to help us keep these patients, all of us active. So it's very exciting. And I'm not talking about centuries from now. I'm talking a few years from now. I think we'll have, and a lot of this will have come out of these exchange of ideas that we've been having here over the past three years. And this is not finishing after the conference because after the conference, the presenter, the scientists will keep collaborating. And that's what's amazing about this. So it's a good way of getting great minds together, exchanging the ideas, finding ways to have a faster path to a good result and great result in validation. And at the end, we're all going to benefit from it. The community here in Vail, but everybody in the U.S. in the world ultimately will benefit from this. So it's pretty exciting.